List of works - Onintza Sagredo

A restricted population of CB1 cannabinoid receptors with neuroprotective activity

scientific article

Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

scientific article published on 5 March 2016

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

scientific article published on August 2009

Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

scientific article published on 15 August 2018

Cannabinoids and neuroprotection in basal ganglia disorders.

scientific article published on 23 June 2007

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

scientific article published on 23 March 2017

Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study.

scientific article published in December 2009

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

scientific article published on 7 October 2010

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

scientific article published on 5 October 2009

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

scientific article published in January 2013

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

scientific article

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

scientific article

New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.

scientific article published on 11 November 2011

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

scientific article

The endocannabinoid system in Huntington's disease.

scientific article published on January 2008

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

scientific article published on 17 October 2013

List of works by Onintza Sagredo

A restricted population of CB1 cannabinoid receptors with neuroprotective activity

Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

Cannabinoids and neuroprotection in basal ganglia disorders.

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study.

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

The endocannabinoid system in Huntington's disease.

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.